公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2005 | Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever | Jun H.X.; Zhixiang S.; Chun W.; Reksodiputro A.H.; Ranuhardy D.; Tamura K.; Matsumoto T.; Lee D.-G.; Purushotaman S.V.; Lim V.; Ahmed A.; Hussain Y.; Chua M.; Ong A.; Liu C.-Y.; PO-REN HSUEH ; Lin S.-F.; Liu Y.-C.; Suwangool P.; Jootar S.; Picazo J.J. | International Journal of Antimicrobial Agents | 26 | 14 | |
2021 | Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan | Yin O.; Iwata H.; CHIA-CHI LIN ; Tamura K.; Watanabe J.; Wada R.; Kastrissios H.; AbuTarif M.; Garimella T.; Lee C.; Zhang L.; Shahidi J.; LaCreta F. | Clinical Pharmacology and Therapeutics | 22 | 15 | |
2019 | Insights into Breast Cancer in the East vs the West: A Review | Yap Y.-S.; YEN-SHEN LU ; Tamura K.; Lee J.E.; Ko E.Y.; Park Y.H.; Cao A.-Y.; CHING-HUNG LIN ; Toi M.; Wu J.; Lee S.-C. | JAMA Oncology | 84 | 66 | |
2018 | Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study | Gambacorti-Passerini C.; Orlov S.; Zhang L.; Braiteh F.; Huang H.; Esaki T.; Horibe K.; Ahn J.-S.; Beck J.T.; Edenfield W.J.; Shi Y.; Taylor M.; Tamura K.; Van Tine B.A.; SHANG-JU WU ; Paolini J.; Selaru P.; Kim T.M. | American Journal of Hematology | 70 | 63 | |
2021 | An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer | YEN-SHEN LU ; Yeo W.; Yap Y.-S.; Park Y.H.; Tamura K.; Li H.; Cheng R. | Targeted Oncology | 5 | 5 | |
2020 | Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study | Mehnert J.M.; Bergsland E.; O’Neil B.H.; Santoro A.; Schellens J.H.M.; Cohen R.B.; Doi T.; Ott P.A.; Pishvaian M.J.; Puzanov I.; Aung K.L.; CHIUN HSU ; Le Tourneau C.; Hollebecque A.; Élez E.; Tamura K.; Gould M.; Yang P.; Stein K.; Piha-Paul S.A. | Cancer | 83 | 75 | |
2021 | Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs | Hata T.; Nakamura K.; Yonemori K.; Noguchi E.; Watanabe M.; Sohn J.; YEN-SHEN LU ; Yap Y.-S.; Tamura K.; Fujiwara Y. | Clinical and Translational Science | 2 | 1 | |
2019 | Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer | Mehnert J.M.; Varga A.; Brose M.S.; Aggarwal R.R.; CHIA-CHI LIN ; Prawira A.; De Braud F.; Tamura K.; Doi T.; Piha-Paul S.A.; Gilbert J.; Saraf S.; Thanigaimani P.; Cheng J.D.; Keam B. | BMC Cancer | 133 | 108 |